Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

IP Group has set up a joint venture with China Everbright that will invest in Chinese subsidiaries of the commercialisation firm’s portfolio through a $235m-target fund.

Zymergen has purchased Lodo Therapeutics, which is advancing Rockefeller research, for an undisclosed sum five years after the company raised its only funding round.

UC San Francisco spinout Effector Therapeutics is set to go public through a reverse merger with Locust Walk Acquisition Corp that includes a $60m PIPE financing.

Columbia’s Text IQ has been bought by Relativity for an undisclosed amount.

Bascom Palmer Eye Institute’s spinout is working on AR/VR vision diagnosis and augmentation technology and has secured more cash five months after its seed funding.

Main Sequence Ventures-backed Amber has closed a $15.5m series B round led by Commonwealth Bank.

IP Group has participated in a $92m series C round for Pulmocide, a developer of treatments for respiratory diseases that was spun out of Imperial College London.

Columbia has taken an equity stake in the antiviral therapeutics producer, co-founded by two of its faculty members.

PreSeed Ventures-backed Pento has secured $15.6m in a series A round led by General Catalyst, bringing its total financing to $19.1m.